Vasopressin-Based Versus Norepinephrine-Based Strategy in Vasoplegic Syndrome After Cardiac Surgery: A Randomized...

Area of Science:

• Cardiology
• Critical Care Medicine
• Pharmacology

Background:

• Vasoplegic syndrome (VS) is a common complication following cardiac surgery, typically managed with norepinephrine (NE).
• Effective management of post-cardiopulmonary bypass (CPB) vasoplegia is crucial for patient outcomes.

Purpose of the Study:

• To compare the clinical and physiological effects of a vasopressin (VP)-based strategy versus an NE-based strategy as first-line management for VS post-CPB.
• To evaluate the impact of VP versus NE on length of hospital stay, hemodynamic stability, and other key clinical markers.

Main Methods:

• A single-center, randomized controlled trial involving 90 patients with VS post-CPB.
• Patients were randomized to receive either a VP-based or NE-based vasopressor strategy.
• Primary outcome was length of hospital stay; secondary outcomes included hemodynamic parameters, lactate clearance, cardiac biomarkers, and endocrine markers.

Main Results:

• The VP-based strategy resulted in a significantly shorter length of hospital stay compared to the NE-based strategy (p=0.0036).
• Patients receiving VP demonstrated improved hemodynamic stability, including higher mean arterial pressure and systemic vascular resistance index.
• VP group showed faster lactate normalization and a greater reduction in cardiac biomarkers, with balanced adverse event rates.

Conclusions:

• A VP-based strategy offers effective hemodynamic stabilization and is associated with reduced hospital stays in patients with VS post-cardiac surgery.
• Vasopressin presents a viable early alternative or adjunctive vasopressor option for managing post-operative vasoplegic syndrome.